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ABSTRACT
Background Inherited cystic kidney disorders are a
common cause of end-stage renal disease. Over 50
ciliopathy genes, which encode proteins that influence
the structure and function of the primary cilia, are
implicated in cystic kidney disease.
Methods To define the phenotype and genotype of
cystic kidney disease in fetuses and neonates, we
correlated antenatal ultrasound examination and
postnatal renal ultrasound examination with targeted
exon sequencing, using a renal gene panel. A cohort of
44 families in whom antenatal renal ultrasound scanning
findings in affected cases included bilateral cystic kidney
disease, echogenic kidneys or enlarged kidneys was
investigated.
Results In this cohort, disease phenotypes were severe
with 36 cases of stillbirth or perinatal death. Extra renal
malformations, including encephalocele, polydactyly and
heart malformations, consistent with ciliopathy
phenotypes, were frequently detected. Renal gene panel
testing identified causative mutations in 21 out of 34
families (62%), where patient and parental DNA was
available. In the remaining 10 families, where only
parental DNA was available, 7 inferred causative
mutations were found. Together, mutations were found
in 12 different genes with a total of 13 novel pathogenic
variants, including an inferred novel variant in NEK8.
Mutations in CC2D2A were the most common cause of
an antenatal cystic kidney disease and a suspected
ciliopathy in our cohort.
Conclusions In families with ciliopathy phenotypes,
mutational analysis using a targeted renal gene panel
allows a rapid molecular diagnosis and provides
important information for patients, parents and their
physicians.
INTRODUCTION
The formation of cysts in kidney is a disease pheno-
type common to many inherited human diseases.1
Kidney cysts are fluid-filled epithelial lined struc-
tures arising from dilation in any part of the
nephron or collecting duct. Cystic kidney disorders
are a common cause of end-stage renal disease
(ESRD). It is estimated that the prevalence of cystic
kidney disease is 4.81% in the Arabian Gulf
countries.2
Ciliopathy syndromes are inherited syndromes
that are frequently associated with cystic kidneys
and to date, mutations in over 50 genes have been
identified.3 These include autosomal-dominant
polycystic kidney disease (ADPKD), autosomal-
recessive polycystic kidney disease (ARPKD),
various forms of nephronophthisis (NPHP),
Joubert syndrome ( JBTS), Meckel–Gruber syn-
drome (MKS), Bardet–Biedl syndrome (BBS) and
many others.4 ADPKD is common and accounts
for approximately 5–10% of the ESRD cases
worldwide.5 Mutations in two genes, PKD1 (85%
of patients with ADPKD) and PKD2 (15% of
patients with ADPKD) underlie ADPKD.6 One to
two per cent of patients with ADPKD may present
as neonates with cystic kidneys.7 Biallelic muta-
tions/variants in PKD1 and PKD2 have been
described to give a severe neonatal onset of cystic
kidney disease.8 9
ARPKD is a rarer condition affecting 1 in every
20 000 live births.10 It may be diagnosed in utero
or prenatally by sonography showing bilateral large
echogenic kidneys, and oligohydramnios in the
most severe cases. Mutations in the polycystic
kidney and hepatic disease 1 (PKHD1) gene are
responsible for ARPKD, the severity of which
depends on the type of mutations.11 The PKHD1
gene is located on chromosome 6p21 and encodes
a fibrocystin protein that localises to the primary
cilium of renal epithelial cells. There is a high risk
of fetal presentation and neonatal death if the fetus
carries two truncating mutations.12
Inherited ciliopathies may also cause multisystem
pathology, which may be severe and result in early
death for many patients. Aside from cystic kidney
disease, other common clinical features of ciliopa-
thies include hepatobiliary disease, laterality
defects, polydactyly, agenesis of corpus callosum,
retinal degeneration and occipital encephalocele.13
Ciliopathies with prominent renal phenotypes
include NPHP, JBTS and MKS.
NPHP is an autosomal-recessive disorder respon-
sible for 6–10% of ESRD in children.14 NPHP is
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characterised by cysts that are typically restricted to the cortico-
medullary junction region of the kidney, and the kidney size is
normal or reduced.15 The disease is genetically heterogeneous.
Mutations in over 20 different recessive genes (including
NPHP1–NPHP19, AHI1 and XPNPEP3) have been identified in
about 50% of NPHP patients.16 Infantile NPHP is a disease that
progresses to ESRD usually before the age of 2 years and is
characterised by cortical microcysts associated with tubulointer-
stitial lesions. Classically, it is linked to NPHP2/INVS gene
encoding inversin, but patients carrying NPHP3 mutations may
also develop the infantile phenotype frequently associated with
liver involvement.17
JBTS is neurodevelopmental disorder characterised by cere-
bellar vermis aplasia (CVA), a significant malformation of the
cerebellum that is linked to ataxia and may be seen on brain
MRI as ‘molar tooth sign’.18 JBTS follows an autosomal-
recessive inheritance pattern and there are currently over 26
known causative genes.19–21 JBTS may be associated with cystic
renal disease in a subset of cases.
MKS is a prenatally lethal autosomal-recessive condition char-
acterised by occipital encephalocele, bilateral renal cystic dyspla-
sia, hepatic ductal proliferation, fibrosis, cysts and polydactyly.22
Patients with MKS invariably die from respiratory and/or renal
failure. Genetic heterogeneity of MKS has been established with
now 13 reported genes involved.23–25
For many of these ciliopathy syndromes, significant pheno-
typic variability has been observed even between members of
the same family, making clinical diagnosis, prediction of clinical
progression and genetic counselling a challenge.
Antenatal screening using ultrasound scanning (USS) is a
means by which cystic kidney disease can be readily detected.
Serial ultrasound evaluation starting from 11 weeks of gestation
onwards can be used as a screening modality.26 Abnormal find-
ings that point towards a renal ciliopathy include increased size
of kidneys, a bright echotexture (hyperechogenicity) and a loss
of the normal corticomedullary differentiation. Perinatal ultra-
sound appearance of kidneys can look similar in fetuses with
ARPKD, perinatal-onset ADPKD, MKS and some forms of
NPHP. In addition to renal anomalies, prenatal ultrasound can
detect other features of ciliopathies such as encephalocele, poly-
dactyly, situs inversus, agenesis of the corpus callosum, Dandy–
Walker malformation, fibrosis of the liver and structural heart
defects.22
In this study, we have combined antenatal ultrasound examin-
ation of the fetus and targeted molecular genetic ‘panel testing’
for inherited renal disorders to characterise a cohort of Saudi
Arabian patients who presented antenatally with features of an
inherited renal ciliopathy.
MATERIALS AND METHODS
Study cohort
The cohort consists of 44 Saudi Arabian families where there
was evidence of antenatal USS anomalies of the kidney, which
included cystic kidney disease, enlarged kidneys and echogenic
kidneys. Additional antenatal USS findings including central
nervous system (CNS) anomalies (encephalocele, CVA, ventricu-
lomegaly), cardiac defects (congenital heart malformation, peri-
cardial effusion) and skeletal defects (narrow thorax,
polydactyly) were documented. Clinical phenotypes postnatally
were also reviewed, including postnatal renal USS. For molecu-
lar genetic investigations, the cohort was divided into two
groups: Group A, where DNA was available from the affected
fetuses and their parents (n=34 families) and Group B, where
DNA was available from both parents but not the affected child
(n=10 families) (table 1). Following informed consent, DNA
was extracted from available chorionic villus sampling, amniotic
fluid, placental blood or peripheral blood cells using the Gentra
Systems PUREGENE DNA Isolation kit (Qiagen, Valencia,
California, USA). Ethical and study permissions were approved
by the Research Advisory Council of King Faisal Specialist
Hospital, Riyadh, Saudi Arabia (RAC#2050 045). We confirm
that all the diagnostic genetic work was performed in Saudi
Arabia with full ethical approval. The UK centre acted in an
advisory and strategic manner to direct the study.
Antenatal USS examination
Prenatal anatomy USS examination was performed at the
Obstetrics and Gynecology Department, King Faisal Specialist
Hospital and Research Centre, between weeks 18 and 22 of
pregnancy. For cases with a known family history of cystic
kidney disease/ciliopathy serial, antenatal USS examinations
started between 12 and 22 weeks. For new referrals and
unknown family history, antenatal USS started at the first visit.
Fetal anatomy was reported as either normal or abnormal with
explanations for features that includes cranium, cerebral ventri-
cles, posterior fossa, face, spine, chest, cardiac four-chamber
view, cardiac outflow tracts, heart axis, cardiac situs, stomach,
bowel, kidneys, bladder, abdominal cord insertion, number of
cord vessels, upper extremities and presence of hands, and lower
extremities and presence of feet. Published reference values for
renal length and volume27 and for renal volumes based on three-
dimensional ultrasound28 were used. Fetal death was defined as
an intrauterine death greater than 10 weeks of gestation. A peri-
natal death is defined as a death within 7 days of birth, and an
infant death is defined as a death within 1 year of birth.
Maternal cell contamination and molecular karyotyping
In all fetal DNA samples, maternal cell contamination was
excluded by using the AmpFLSTR Identifiler PCR Amplification
Kit as described by the manufacturer (Applied Biosystems, Life
Technologies, Paisley, UK). Where available fetal DNA was used
for molecular karyotyping (Affymetrix CytoScan HD Array Kit,
Santa Clara, California, USA) to exclude chromosomal aneu-
ploidy and to determine regions of homozygosity in the affected
patient.
Targeted renal genes panel and next generation sequencing
A customised 90 renal genes panel that includes ciliopathy
genes (including 3 polycystic kidney disease genes, 10 NPHP
genes, 9 JBTS genes and 11 MKS genes) as well as and other
inherited renal disorders (see online supplementary table S1)
was prepared using Life Technologies proprietary AmpliSeq
multiplexing assay. This panel has previously undergone valid-
ation for its analytical sensitivity and specificity using 107 renal
patients and had 89% base reads on target with a read depth
(base coverage) of 840 after alignment and a of 98% coverage
of all genes.29 All samples were prepared within the Saudi
Human Genome Project Laboratories and loaded onto a Proton
I chip, and sequencing was performed on an Ion Proton system
(Ion Torrent—Life Technologies) as recommended by the manu-
facturer and as previously described.29
NGS analysis pipeline
The analysis pipeline for processing the next generation sequen-
cing (NGS) reads went through several steps. Reads were exam-
ined for quality and parts of reads with low-quality value were
trimmed out. The reads were then aligned to the human refer-
ence genome GRCh37/Hg19 with the Torrent Mapping
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Table 1 Clinical and molecular findings in cohort of antenatal cystic kidney disease and ciliopathy phenotypes
A or B Family Consanguinity Outcome
Renal
phenotype
Oligohydramnios/
anhydramnios Encephalocele
Other CNS
abnormalities
Skeletal/
growth
malformations
Other
defects
Number
of other
affected
fetus/
siblings
Segregation
and
unaffected
sib Gene Mutation
Remarks and ExAC
MAF
A FT-3 Yes Fetal
death
Cystic Yes Polydactyly 0 m,f (1×
unaffected
sib-het)
B9D1 Homo
c.508_510delCTC
p.L170del
Novel
A FT-1 Yes Fetal
death
Enlarged,
echogenic
with cysts
Yes Yes Polydactyly Cystic
hygroma
2 m,f CC2D2A Homo c.3084delG
p.R1028Rfs*3
Reported30
(MAF=0.00002548)
A FT-6 Not known Fetal
death
Cystic Yes CVA, dilated
cisterna magna,
corpus callosum
agenesis
0 m,f (1×
unaffected
sib-het)
CC2D2A Homo c.3364C>T p.
P1122S
Reported31
A FT-8 Yes Fetal
death
Enlarged,
echogenic
with cysts
Yes Yes Corpus callosum
agenesis and
holoprosencephaly
1 m,f CC2D2A Homo c.4531T>C p.
W1511R
Reported32
A FT-14 Yes Fetal
death
Cystic Yes Spina bifida 2 m,f CC2D2A Homo c.4531T>C p.
W1511R
Reported32
A FT-15 Yes Fetal
death
Cystic Yes Intrauterine
growth
restriction
2 m,f CC2D2A Homo c.3084delG
p.R1028Rfs*3
Reported30
(MAF=0.00002548)
A FT-21 Yes Fetal
death
Cystic Yes Clubfoot 0 m.f CC2D2A Homo c.3084delG
p.R1028Rfs*3
Reported30
(MAF=0.00002548)
A FT-26 Yes Fetal
death
Cystic Yes Ascites 2 m CC2D2A Homo c.4437
+1G>A
Novel
A FT-7 Not known Alive at 6
m
Cystic CVA 0 m,f CEP290 Homo c.5668G>T p.
G1890*
Reported33
(MAF=0.0001432)
A FT-9 Yes Perinatal
death
Enlarged
echogenic
Yes Ventriculomegaly 1 m,f
(unaffected
sib –het,
unaffected sib
–wt)
INVS Homo c.1760delA
p.Q587Rfs*2
Novel
A FT-27 Yes Fetal
death
Cystic Yes Yes Clubfoot 1 m MKS1 Homo c.417
+1G>A
Novel
A FT-5 Yes Fetal
death
Cystic Yes Yes 3 m,f MKS1 Homo c.1066C>T
p.Q356*
Novel
A FT-13 Yes Fetal
death
Cystic Yes 3 m MKS1 Homo c.1066C>T
p.Q356*
Novel
A FT-31 Yes Infant
death (8
mo)
Cystic Congenital
heart
malformation,
lung
hypoplasia
0 m,f PKHD1 Homo c.4870C>T p.
R1624W
Reported30
(MAF=0.0001812)
A FT-33 Yes Alive at
12 mo
Cystic Hepatic cysts 0 m,f PKHD1 Homo c.4870C>T p.
R1624W
Reported30
(MAF=0.0001812)
Continued
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Table 1 Continued
A or B Family Consanguinity Outcome
Renal
phenotype
Oligohydramnios/
anhydramnios Encephalocele
Other CNS
abnormalities
Skeletal/
growth
malformations
Other
defects
Number
of other
affected
fetus/
siblings
Segregation
and
unaffected
sib Gene Mutation
Remarks and ExAC
MAF
A FT-34 Yes Alive at
14 mo
Cystic 0 m,f PKHD1 Homo c.4870C>T p.
R1624W
Reported30
(MAF=0.0001812)
A FT-19 Yes Fetal
death
Cystic Yes 3 m,f (1×
unaffected
sib-het)
RPGRIP1L Het c.640G>A p.
V214I
Het c.685G>A p.
A229T
V214I Reported34
(V214I,
MAF=0.0005292)
A FT-20 Not known Perinatal
death
Enlarged
echogenic
Yes Yes Micrognathia 0 m,f TCTN2 Homo c.1852C>T
p.Q618*
Novel
A FT-10 Yes Fetal
death
Enlarged,
echogenic
with cysts
Yes Narrow thorax,
dolichocephaly
0 m,f TMEM67 Homo c.457T>G
p.C153G
Novel
A FT-22 Yes Fetal
death
Enlarged
cystic
Yes CVA,
hydrocephalus
Congenital
heart
malformation,
pericardial
effusion
2 m,f TMEM67 Homo
c.1413-2A>G
Novel
A FT-18 Yes Perinatal
death
Cystic Yes Yes Corpus callosum
agenesis
Clubfoot Hepatic cysts 1 m,f TMEM231 Homo c.751G>A
p.V251I
Reported32
A FT-23 Yes Fetal
death
Increased
echogenicity
Yes CVA, dilated
cisterna magna,
Dandy–Walker
malformation
Pericardial
effusion
1 Unsolved
A FT-28 Yes Fetal
death
Increased
echogenicity
Yes Dandy-Walker
malformation
Polydactyly 2 Unsolved
A FT-4 Yes Fetal
death
Cystic Yes CVA, dilated
cisterna magna
Narrow thorax Pericardial
effusion
1 Unsolved
A FT-12 Yes Fetal
death
Increased
echogenicity
Yes Dolichocephaly 2 Unsolved
A FT-11 Yes Perinatal
death
Cystic Yes 0 Unsolved
A FT-17 No Alive at
36 mo
Cystic CVA, dilated
cisterna magna
0 Unsolved
A FT-24 Yes Fetal
death
Cystic Yes Narrow thorax 0 Unsolved
A FT-25 Yes Fetal
death
Cystic Yes 0 Unsolved
A FT-29 No Fetal
death
Cystic Yes Yes 0 Unsolved
A FT-30 Yes Fetal
death
Cystic Yes Ventriculomegaly 1 Unsolved
A FT-16 Not known Fetal
death
Enlarged
kidneys
Yes 0 Unsolved
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Table 1 Continued
A or B Family Consanguinity Outcome
Renal
phenotype
Oligohydramnios/
anhydramnios Encephalocele
Other CNS
abnormalities
Skeletal/
growth
malformations
Other
defects
Number
of other
affected
fetus/
siblings
Segregation
and
unaffected
sib Gene Mutation
Remarks and ExAC
MAF
A FT-2 Yes Fetal
death
Cystic Yes CVA, dilated
cisterna magna
3 Unsolved
A FT-32 Yes Alive at
20 mo
Cystic Yes 0 Unsolved
B FT-35 Yes Fetal
death
Cystic CVA, dilated
cisterna magna
3 m,f CC2D2A Presumed homo
c.3084delG p.
R1028Rfs*3
Reported30
(MAF=0.00002548)
B FT-40 Yes Fetal
death
Cystic 1 m,f CEP290 Presumed homo
c.3777_3778delAG
p.R1259Sfs*16
Novel
B FT-43 Yes Fetal
death
Cystic Yes 2 m,f MKS1 Presumed homo
c.1066C>T p.
Q356*
Novel
B FT-36 Yes Fetal
death
Cystic Yes CVA, dilated
cisterna magna
Bilateral bowed
femurs
0 m,f NEK8 Presumed homo
c.1401G>A p.
W467*
Novel
(MAF=0.000008237)
B FT-41 Yes Fetal
death
Cystic Congenital
heart
malformation
1 m,f NPHP3 Presumed homo
c.2694-1_-2delAG
Novel
(MAF=0.0003553)
B FT-45 Yes Fetal
death
Cystic Yes Hepatomegaly 1 m,f PKHD1 Presumed homo
c.3539G>A p.
G1180E
Novel
B FT-42 Yes Fetal
death
Cystic 2 m,f TCTN2 Presumed homo
c.252_253delTG
Novel
B FT-37 Yes Fetal
death
Cystic 1 Unsolved
B FT-38 Yes Fetal
death
Cystic 0 Unsolved
B FT-44 Yes Fetal
death
Cystic 1 Unsolved
Novel mutations are in bold.
A: samples where DNA from affected and parent(s) was available. B: Samples where maternal and paternal DNA was available and mutation is presumed (with a 25% chance) to be causative.
CVA, cerebellar vermis aplasia; CNS, central nervous system; f, father; het, heterozygous; homo, homozygous; m, mother; MAF, minor allele frequency; mo, month; sib, sibling.
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Alignment Program (TMAP) Aligner software. Once the reads
were aligned, the variants were called using the Torrent Variant
Caller (TVC) program. The TMAP and the TVC programs are dis-
tributed as part of the Torrent Suite (https://github.com/iontorrent/
TS) package. The resulting variant files were stored in variant call
format (VCF) files. The VCF file generated for each sample was
processed through an annotation pipeline against databases such
as OMIM, GenBank, dbSNP, 1000 genome project, Human Gene
Mutation Database, and a local database (SGP737) of 550 patients
containing Arab-specific variants. Variants with a minor allele fre-
quency (MAF) >1% were discounted.
In addition to allele frequency, annotation provides pathogen-
icity scores, homozygosity/heterozygosity, read quality scores
and other parameters used to identify candidate causative var-
iants. All NGS and targeted sequencing and bioinformatics ana-
lysis were performed at the Saudi Human Genome Project
Laboratories at KFSHRC and KACST.
For predicting the damaging effect of the reported mutation,
four in silico prediction tools were used: PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph/), Provean (http://provean.jcvi.
org/index.php), MutationTaster (http://www.mutationtaster.org/)
and Human Splicing Finder (http://www.umd.be/HSF/#).
Reported allele frequency of all putative pathogenic variants was
determined using the ExAC database (http://exac.broadinstitute.
org/), and evolutionary conservation was determined from
sequence alignments using MutationTaster and UCSC (https://
genome.ucsc.edu).
Sanger sequencing
Direct sequencing of PCR amplicons was carried out to confirm
positive gene panel results. PCR was performed using Qiagen
(Manchester, UK) master mix kit. Oligonucleotide primers for
PCR amplification of targeted genomic DNA were designed
using Primer3 software (http://frodo.wi.mit.edu/) and synthe-
sised by Metabion International AG (Munich, Germany).
Primer sequences are available on request. Following treatment
with the Agencourt AMPure PCR purification system
(Agencourt Bioscience, Beverly, Massachusetts, USA), products
were sequenced using BigDye Terminator Cycle Sequencing kit
(PE Applied Biosystems, Massachusetts, USA) and run on an
ABI 3730xl capillary sequencer. Sequences were analysed using
Mutation Surveyor software V.3.24 (SoftGenetics LLC, State
College, Pennsylvania, USA).
RESULTS AND DISCUSSION
A cohort of 44 families were analysed, where 38 (86%) were
known to be consanguineous and 26 (59%) had more than one
affected fetus. The antenatal renal USS findings included either
bilateral cystic kidney disease, echogenic kidneys or enlarged
kidneys in all cases (table 1). Antenatal USS also detected extra-
renal malformations at a high rate (figure 1): 25 (57%) had
oligohydramnios or anhydramnios, 14 (32%) had encephalo-
cele and 9 (20%) had CVA. Other anomalies included limb
defects including polydactyly and structural cardiac defects. The
phenotype of this cohort was extremely severe with 38 (86%)
cases dying as stillborn infants or perinatally. Only six cases sur-
vived the perinatal period (table 1).
Where patient DNA was available (group A, n=34), none of
the cases had evidence of chromosomal aneuploidy (data not
shown) and therefore malformation syndromes associated with
renal cysts, such as trisomy 13 (Patau), trisomy 18 (Edward) and
trisomy 21 (Down), were excluded.
Using the renal gene panel in this cohort, 96.98% coverage of
target genes was achieved, with an average base coverage of
Figure 1 Prenatal ultrasound images of affected fetuses. (A and B)
FT-8: transverse view of the fetal abdomen at 33 weeks of gestation
(A), showing enlarged echogenic kidneys. Transverse view of the fetal
head at 33 weeks of gestation (B), showing a cystic mass arising from
the occipital area of the fetal head representing an encephalocele.
(Genotype: CC2D2A homozygous mutation.) (C) FT-10: a transverse
view of the fetal abdomen at 23 weeks of gestation, showing enlarged
echogenic kidneys with cystic areas. (Genotype: TMEM67 homozygous
mutation.) (D) FT-20: a transverse view of the fetal kidneys at
33 weeks, showing enlarged echogenic kidneys. (Genotype: TCTN2
homozygous mutation.) (E and F) FT-1: a transverse view of the fetal
kidneys at 31 weeks of gestation (E), showing enlarged echogenic
cystic kidneys. A transverse view of the fetal head at 31 weeks of
gestation (F), showing a cystic mass arising from the fetal occiput,
which represents an encephalocele. (Genotype: CC2D2A homozygous
mutation.) (G) FT-9: a transverse view of the fetal abdomen at
27 weeks of gestation showing bilateral enlarged echogenic kidneys.
(Genotype: INVS homozygous mutation.) (H) FT-13: a sagittal view of a
fetus at 12 weeks of gestation showing a mass arising from the
posterior aspect of the fetal head, which represents an encephalocele.
(Genotype: MKS1 homozygous mutation). (I) FT-22: a transverse view
of the fetal abdomen at 18 weeks, showing enlarged kidneys with
cystic changes. (Genotype: TMEM67 homozygous mutation.) ( J) FT-21:
a transverse view of the fetal head at 16 weeks of gestation, showing a
mass arising from the posterior aspect of the fetal head, which
represents an encephalocele. (Genotype: CC2D2A homozygous allele.)
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>500. Twenty-one patients from 34 families in cohort A had a
molecular genetic diagnosis (62% mutation detection rate).
Seven families from the 10 families in cohort B had an inferred
molecular genetic diagnosis by the finding of identical patho-
genic alleles in both parents who were known to be consanguin-
eous. The chances of the affected child inheriting both these
alleles would be 25%. The identified rare alleles identified in
these parental samples are listed in online supplementary table
S2. In each of the families, there is only a single rare heterozy-
gous change that was identified and confirmed using Sanger
sequencing in both parents allowing a genetic diagnosis to be
inferred (see online supplementary figure S1). All mutations
identified were confirmed and segregation analysis was per-
formed (including screening unaffected siblings) using Sanger
sequencing. Mutations in genes B9D1, CC2D2A, CEP290,
INVS, MKS1, NEK8, PKHD1, RPGRIP1L, TCTN2,
TMEM67 and TMEM231 were identified (table 1) with a total
of 13 novel variants detected in this study (table 2 and figure 2).
Pathogenic rare (<1% MAF) sequence variants were not
detected in the other renal panel genes, in particular digenic or
oligogenic changes in renal ciliopathy genes were not seen. A
common RPGRIP1L missense variant in its heterozygous state
was identified as a third allele in two cases and is discussed
below. Consistent with the lethal phenotypes seen in this
cohort, mutations in B9D1, CC2D2A, CEP290, MKS1,
RPGRIP1L, TCTN2, TMEM67 and TMEM231 are all known to
cause a MKS phenotype. Mutations in INVS and NEK8 have
been reported in severe neonatal forms of NPHP with numer-
ous extrarenal features.35 Phenotypes in some of the patients
with mutations with PKHD1 mutations were comparatively less
severe, accounting for three of the cases which survived beyond
the perinatal period.
In group A (34 families), homozygous mutations were
detected in 20 families with just one family with compound het-
erozygous mutations (FT-19), in keeping with the known high
rates of consanguinity. In group B (10 families), homozygous
mutations were inferred by finding identical heterozygous var-
iants in both parents in seven cases, consistent with the known
parental consanguinity. These mutations were presumed to be
found in their homozygous state in the affected patient.
Unfortunately, direct sequencing of patient DNA or any
unaffected siblings was not available in these cases. All muta-
tions detected were either previously reported (and known to
be pathogenic) or novel and predicted to be pathogenic by using
in silico scores (table 2). Novel mutations were all homozygous
(or inferred to be homozygous from parental samples) and
included predicted missense, frameshift, nonsense and splicing
defects. The types of mutations detected in this cohort seem to
correlate closely with the phenotypes observed. Most mutations
detected were truncating, frameshift and splice site mutations.
These mutations were often lethal, causing fetal death or peri-
natal death. In this study, six missense mutations resulted in
fetal or perinatal death.
Mutations in CC2D2A gene were the most common cause of
antenatally detected cystic kidney disease in our cohort,
accounting for eight cases. All patients with CC2D2A mutations
had severe CNS abnormalities; six had evidence of an encepha-
locele indicative of a MKS phenotype and two had evidence of
Table 2 In silico analysis of novel mutations
Gene Mutation
Reference
sequence
Mutation
type Provean PolyPhen-2
Mutation
Taster
Human
Splicing
Finder ExAC database
Evolutionary
conservation
B9D1 c.508_510delCTC
(p.L170del)
NM_015681 Indel Deleterious
(−7.568)
N/A Disease causing
(0.989)
Absent Caenorhabditis.
elegans
CC2D2A c.4437+1G>A NM_001080522 Splice site N/A N/A N/A Donor site
broken
Absent Perkinsus.
marinus
CEP290 c.3777_3778delAG
(p.R1259Sfs*16)
NM_025114 Deletion,
frameshift
N/A N/A Disease causing
(1.000)
Absent Danio rerio
INVS c.1760delA
(p.Q587Rfs*2)
NM_014425 Deletion,
frameshift
N/A N/A Disease causing
(1.000)
Absent Xenopus
tropicalis
MKS1 c.417+1G>A NM_017777 Splice site N/A N/A N/A Donor site
broken
Absent D. rerio
MKS1 c.1066C>T
(p.Q356*)
NM_017777 Nonsense N/A N/A Disease causing
(1.000)
Absent D. rerio
NEK8 c.1401G>A
(p.W467*)
NM_178170 Nonsense N/A N/A Disease causing
(1.000)
1 het. allele reported
(MAF=0.000008237)
X. tropicalis
NPHP3 c.2694-1_-2delAG NM_153240 Deletion,
frameshift
N/A N/A N/A Acceptor
site broken
43 het. alleles reported
(MAF=0.0003553)
D. rerio
PKHD1 c.3539G>A
(p.G1180E)
NM_138694 Missense Deleterious
(−6.296)
Probably
damaging
(0.999)
Disease causing
(0.761)
Absent Mus musculus
TCTN2 c.252_253delTG
(p.V85Dfs*24)
NM_024809 Deletion,
frameshift
N/A N/A Disease causing
(1.000)
Absent X. tropicalis
TCTN2 c.1852C>T
(p.Q618*)
NM_024809 Nonsense N/A N/A Disease causing
(1.000)
Absent X. tropicalis
TMEM67 c.457T>G
(p.C153G)
NM_153704 Missense Deleterious
(−7.289)
Probably
damaging
(1.000)
Disease causing
(0.999)
Absent C. elegans
TMEM67 c.1413-2A>G NM_153704 Splice site N/A N/A N/A Acceptor
site broken
Absent D. rerio
Evolutionary conservation at the protein level for non-synonymous changes was analysed by comparing the wild-type amino acid in the human with other orthologues in lower species.
The lowest species where exact conservation of amino acid was preserved is shown.
Het, heterozygous; MAF, minor allele frequency; N/A, not applicable.
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CVA with a dilated cisterna magna, in keeping with a JBTS
phenotype. Typical MKS phenotypes were seen in three patients
with MKS1 mutations, which included two novel changes
(table 2). The novel nonsense MKS1 mutation (p.Q356*) was
present in two families (FT-5 and FT-13), suggesting that these
families were related. In family FT-18, the TMEM231 mutation
(p.V251I) led to perinatal death in two fetuses. The mutation is
predicted to cause a splicing defect (table 2), due to its position
as the last nucleotide in exon 4 of the TMEM231, although it
appears to be a missense change.
PKHD1 gene mutations were found in four families. One case
(FT-31) had associated lung hypoplasia and cardiac malforma-
tions and another (FT-33) had evidence of intrahepatic cysts
(table 1). It has been reported that truncating mutations in
PKHD1 gene may be lethal.12 In this study, mutations detected
in PKHD1 gene were homozygous missense mutations rather
than truncating mutations, one of which was novel
(c.3539G>A; p.G1180E) and led to a perinatal death in the
proband and a sibling (FT-45). Three families shared the
c.4870C>T (p.R1624W) mutation, which has been reported
previously (also in its homozygous state) in a Saudi Arabian
patient, with a ‘later-onset’ ARPKD phenotype.30
Despite known consanguinity, compound heterozygous var-
iants in RPGRIP1L were identified in family FT-19, with four
affected siblings. The first variant c.640G>A (V214I)
(rs139067427) is rare with a reported allele frequency of 0.05%
and is predicted to be pathogenic (table 2). The second
RPGRIP1L variant c.685G>A (p.A229T) (rs61747071) was
identified in this family following Sanger sequencing of exon 6
of RPGRIP1L, as MAF filtering via our data pipeline had
excluded this relatively common variant (MAF of 3.7%). The
pathogenicity of this variant has been previously explored,34
and the variant has been shown to compromise the interaction
of RPGRIP1L with RPGR. To determine the frequency of this
allele in our patient cohort, Sanger sequencing of RPGRIP1L
exon 6 was performed. The rs61747071 variant was also
present heterozygously in affected patients from FT-8 (with a
homozygous CC2D2A missense mutation) and FT-10 (with a
homozygous TMEM67 missense mutation). The additional
pathogenicity of this allele in these patients is unknown.
Compound heterozygous mutations in B9D1 have previously
been associated with MKS,36 but this gene remains a rare cause
of renal ciliopathies. The fetus in this case presented with pos-
terior encephalocele and bilaterally enlarged multicystic dysplas-
tic kidneys and bilateral clubfeet (but not polydactyly). An
additional disease allele in CEP290 identified in the fetus may
have modified the phenotype.36 The B9D1 protein has struc-
tural similarities to MKS1 and similar severe phenotypes would
be predicted. More recently, mutations in B9D1 have been
described in two unrelated patients (aged 7 and 9 years) and
with JBTS and a neurological limited phenotype, suggesting a
wider phenotypic spectrum.37
Mutations in NEK8 are also a rare cause of a renal ciliopathy.
Previously, homozygous mutations in NEK8 have been described
in a Kurdish child with kidney microcysts and likely NPHP,
reaching ESRD at 14 years of age (c.1273C>T, p.H425Y)38 and
in three stillborn fetuses with enlarged cystic kidneys and cystic
changes in the liver and pancreas (c.1795C>T, p.R599*).35
Some fetuses had additional features including heterotaxy,
truncus arteriosus and other structural heart defects, hypoplastic
lungs and skeletal anomalies (bowed femurs). Here, we identi-
fied a single stillborn fetus (FT-36) with a novel nonsense change
in NEK8 (c.1401G>A, p.W467*) who had cystic kidneys, oligo-
hydramnios, CVA and bilateral bowing of the femurs. This
Figure 2 Novel mutations identified in cohort with antenatal cystic kidney disease and ciliopathy phenotypes. (A) Three nonsense (B), four splice
site (C), three frameshift (D), two missense and (E) one deletion novel mutations (boxed) were detected homozygously in patients or heterozygously
in both parents with ciliopathy phenotypes. ( Just one parental chromatogram is shown but a comparison of maternal and paternal chromatograms
is shown in online supplementary figure S1). Family number (FT) is shown as well as mutation and predicted translational changes. Healthy control
sequence is shown alongside. Intron–exon boundaries are marked with a vertical dashed line.
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nonsense mutation is predicted to disrupt the highly conserved
regulator of chromatin condensation 1 (RCC1) domain and is in
proximity to the murine jck mutation (p.G448V).39
Antenatal presentations of cystic kidney disease are often asso-
ciated with severe phenotypes and poor outcomes. These can
include early presentation of ADPKD, or more commonly in
consanguineous families, a presentation of an autosomal-
recessive renal ciliopathy disease, as we have seen in this cohort.
Extrarenal manifestations on the antenatal USS such as encepha-
locele and CVA may suggest MKS or JBTS phenotypes, respect-
ively. Other features such as polydactlyly and thoracic cage
abnormalities may point towards other ciliopathies such as
BBS40 or skeletal dysplasias such as Jeune syndrome.41
Screening for ciliopathy genes in the diagnostic setting, espe-
cially in the perinatal period, is challenging. While whole exome
sequencing (WES) is one possible approach, targeted gene panel
exome sequencing may be preferable in diagnostic laboratories
for specificity, deliverability and low cost. A disease-specific gene
panel approach avoids the common difficulty of reporting sec-
ondary genetic findings that often occurs following WES.
However, any predesigned NGS gene panel will be limited to
known genes directed towards specific phenotypes and will not
allow for recently discovered ciliopathy genes to be screened.
Our gene panel contained 90 genes and included the 3 known
polycystic kidney disease genes (PKD1, PKD2 and PKHD1) and
11 of the 12 known MKS genes (see online supplementary
table S1). However, it included only 10 of the 21 genes known to
cause NPHP and 9 of the 26 JBTS genes. Therefore, our panel
was biased towards (and very effective at) diagnosing MKS in this
cohort with very severe disease phenotypes, but the precise
molecular genetic diagnosis remained unknown in others.
Indeed, in the 14 cases whom had antenatal USS evidence of an
encephalocele suggestive of a MKS phenotype, all except 2 had a
molecular genetic diagnosis. A recent study confirmed the strong
cystic kidney disease phenotype in MKS patients, where cystic
kidneys were found in (97.7%) of MKS cases.22
To improve diagnostic yield, unsolved samples via our panel
gene testing could be subjected to WES, especially in cases
where there are DNA samples available from more than one
affected in each family. However, this approach is more costly
and can be more time consuming, when compared with a tar-
geted panel approach. We hope to develop an updated renal
gene panel in the near future, as the NGS sequencing platform
we have developed will allow for additional genes (and their
amplicons) to be analysed. In this study cohort of antenatal
cases, the mutation detection rate was higher than reported by
others36 42 who used PCR exon sequencing alone. More
recently, a combination of WES and targeted resequencing of a
ciliopathy gene panel was successfully used in a cohort of
patients with Jeune asphyxiating thoracic dystrophy.43
In summary, using a cohort of patients with antenatal evi-
dence of kidney disease and associated ciliopathy syndromes, we
have performed targeted genetic panel testing using patient and/
or parental DNA samples to reveal the molecular genetic diag-
nosis in 64% of patients. Our high detection rate of homozy-
gous disease-causing alleles reflects a high underlying rate of
consanguinity. We would predict a reduction in diagnostic yield
in less consanguineous populations. The genetic spectrum
remains wide and certainly we have not identified a reason to
narrow our diagnostic panel, rather it should be expanded to
capture more recently reported genetic causes of developmental
renal disease. It is interesting to note that CC2D2A mutations
were the commonest cause of an antenatal ciliopathy in our
cohort, but the genetic heterogeneity of inherited cystic kidney
disease is also borne out by our study. In our population, renal
gene panel testing provided diagnostic information that was
valuable to clinicians, genetic counsellors and families. A
molecular genetic diagnosis provides an accurate diagnosis,
which is hugely valuable when there are such severe phenotypes
affecting one or more family members and can be used to
predict recurrence rates and allow planning, including preim-
plantation genetic diagnosis for future pregnancies.
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